Drug Trial Radar · NCT06211023
A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Jan 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
520
Planned (sponsor's estimate)
Start
Feb 15, 2024
Primary completion
Jun 15, 2026
Study completion Jun 15, 2026
Sponsor
- Lead sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, randomized, controlled, two-part study to evaluate the safety and efficacy of SHR-A1921 with or without carboplatin verus investigator's choice of platinum-based doublet chemotherapy in subjects with recurrent epithelial ovarian cancer.
Conditions
- Ovarian Cancer
Interventions
SHR-1921Drug
SHR-1921
carboplatinDrug
carboplatin AUC 4
carboplatinDrug
carboplatin AUC 5
platinum-based doublet chemotherapyDrug
platinum-based doublet chemotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate Assessed by Investigator According to RECIST v1.1Time frame: Screening up to study completion, an average of 1 year
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.